Open AccessPhase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Author(s) -
Shivaani Kummar,
Robert J. Kinders,
Martin Gutierrez,
Larry Rubinstein,
Ralph E. Parchment,
Lawrence R. Phillips,
Jiuping Ji,
Anne Monks,
Jennifer A. Low,
Alice P. Chen,
Anthony J. Murgo,
Jerry M. Collins,
Seth M. Steinberg,
Helen Eliopoulos,
Vincent L. Giranda,
Gary Gordon,
Lee J. Helman,
Robert H. Wiltrout,
Joseph E. Tomaszewski,
James H. Doroshow
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.19.7681
Subject(s) - medicine , pharmacokinetics , parp inhibitor , pharmacology , peripheral blood mononuclear cell , bioavailability , clinical trial , pharmacodynamics , poly adp ribose polymerase , drug , phases of clinical research , clinical endpoint , oncology , polymerase , in vitro , chemistry , biochemistry , gene
We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom